Brought to you by 
QLT gets option to AOS's eye technology
08 Jun 2006
Executive Summary
Ophthalmic drug and device company Advanced Ocular Systems (AOS; formerly Regenera) granted QLT (oncological, eye, skin, and urological diseases) an exclusive worldwide option to license technology for use in treating ophthalmic and inflammatory diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QLT gets option to AOS's eye technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice